About Aceprobe
Aceprobe is a Healthcare company founded in 2009. Healthcare services involving diagnostics, therapy, and biotechnology innovations. Its Indian entity Aceprobe Technologies (India) Private Limited reported revenue of ₹5.08 Cr. Aceprobe offers products and services including Oncology Consult and Cancer Immunotherapy. Its focus areas include Biotechnology, Medical Diagnostics, Genetics Testing and Therapeutics.
Company details
Lives are helped to be explained, mended, and transformed through a fusion of Biomedicine and Biotechnology by Aceprobe. Futuristic healthcare is embraced to achieve Precision Medicine via personal, digital, and functional approaches, while commitment is maintained to the changing needs of clients and the industry. A two-way model ensures equal participation between seekers and providers, guiding clinical decisions with proven expertise in Healthcare Innovations. Biotechnological sciences, regenerative medicine, and neurosciences are traced within the 21st-century economy to secure everyday life, with products and services aiding therapeutic decisions.
- SectorsHealthcare
- Email••••••••
- Legal Name Aceprobe Technologies (India) Pvt. Ltd
- Date of Incorporation 02 Apr, 2009
- Jurisdiction New Delhi, Delhi, India
- Indian entity revenue₹5.08 Cr
FY 2025 · -39% YoY
- Indian entity net profit₹11.2 Lakh
FY 2025 · 2% margin
- Indian entity EBITDA₹22.3 Lakh
FY 2025 · 4% margin
Associated legal entities of Aceprobe
Aceprobe operates through Aceprobe Technologies (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aceprobe Technologies (India) Private Limited CIN U74900DL2009PTC189137 | Active | 02 Apr 2009 | New Delhi, Delhi | ₹5.1 Cr | 2 | View details |
Products & Services of Aceprobe
Aceprobe offers a comprehensive portfolio of products and services, including Oncology Consult and Cancer Immunotherapy.
Second opinions and expert advice for oncology are provided to support treatment plans and rare toxicity management.
CAR-T Cell Therapy is offered as a one-time infusion to recognize and attack cancer cells.
Board of directors of Aceprobe Technologies (India) Private Limited (Aceprobe)
Aceprobe Technologies (India) Private Limited is the primary company behind Aceprobe. The board of Aceprobe Technologies (India) Private Limited currently have 2 directors; the longest-serving is Puneet Chandna, appointed in 2009. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Puneet Chandna DIN 01479564 | Director | 22 Jun 2009 | 17 yrs 4 mo | Aceprobe Technologies (India) Private Limited |
| Bindia Chandna DIN 02689134 | Director | 22 Jun 2009 | 17 yrs 4 mo | Aceprobe Technologies (India) Private Limited |
Financials of Aceprobe
Figures of Aceprobe Technologies (India) Private Limited, the primary company behind Aceprobe, for FY 2025. Revenue was ₹5.08 Cr (-39% year on year). Net profit was ₹11.2 Lakh (2% margin). EBITDA was ₹22.3 Lakh (4% margin). Revenue has grown at a compounded annual rate of +74% over three years and +100% over five years.
- ₹5.08 CrRevenue · FY 2025 · -39% YoY
- ₹11.2 LakhNet profit · 2% margin
- ₹22.3 LakhEBITDA · 4% margin
- ₹1 LakhPaid-up capital
- +74%Revenue CAGR, 3 years
- +100%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Aceprobe Technologies (India) Private Limited are on its company page.
Detailed financial statements for Aceprobe
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aceprobe
Aceprobe was founded in 2009.
The primary company behind Aceprobe, Aceprobe Technologies (India) Private Limited, reported revenue of ₹5.08 Cr for FY 2025, down 39% year on year.
Lives are helped to be explained, mended, and transformed through a fusion of Biomedicine and Biotechnology by Aceprobe. Futuristic healthcare is embraced to achieve Precision Medicine via personal, digital, and functional approaches, while commitment is maintained to the changing needs of clients and the industry. A two-way model ensures equal participation between seekers and providers, guiding clinical decisions with proven expertise in Healthcare Innovations. Biotechnological sciences, regenerative medicine, and neurosciences are traced within the 21st-century economy to secure everyday life, with products and services aiding therapeutic decisions.
Aceprobe offers Oncology Consult and Cancer Immunotherapy.
Aceprobe operates through Aceprobe Technologies (India) Private Limited.
The legal entities of Aceprobe currently have 2 directors, including Puneet Chandna, Bindia Chandna.